Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 257


The Burkholderia pseudomallei Δasd mutant exhibits attenuated intracellular infectivity and imparts protection against acute inhalation melioidosis in mice.

Norris MH, Propst KL, Kang Y, Dow SW, Schweizer HP, Hoang TT.

Infect Immun. 2011 Oct;79(10):4010-8. doi: 10.1128/IAI.05044-11. Epub 2011 Aug 1.


Role of RelA and SpoT in Burkholderia pseudomallei virulence and immunity.

Müller CM, Conejero L, Spink N, Wand ME, Bancroft GJ, Titball RW.

Infect Immun. 2012 Sep;80(9):3247-55. doi: 10.1128/IAI.00178-12. Epub 2012 Jul 9.


Correlates of immune protection following cutaneous immunization with an attenuated Burkholderia pseudomallei vaccine.

Silva EB, Goodyear A, Sutherland MD, Podnecky NL, Gonzalez-Juarrero M, Schweizer HP, Dow SW.

Infect Immun. 2013 Dec;81(12):4626-34. doi: 10.1128/IAI.00915-13. Epub 2013 Oct 7.


Construction and characterization of an unmarked aroC deletion mutant of Burkholderia pseudomallei strain A2.

Srilunchang T, Proungvitaya T, Wongratanacheewin S, Strugnell R, Homchampa P.

Southeast Asian J Trop Med Public Health. 2009 Jan;40(1):123-30.


Characterization of the Burkholderia pseudomallei K96243 capsular polysaccharide I coding region.

Cuccui J, Milne TS, Harmer N, George AJ, Harding SV, Dean RE, Scott AE, Sarkar-Tyson M, Wren BW, Titball RW, Prior JL.

Infect Immun. 2012 Mar;80(3):1209-21. doi: 10.1128/IAI.05805-11. Epub 2012 Jan 17.


Lipopolysaccharide from Burkholderia thailandensis E264 provides protection in a murine model of melioidosis.

Ngugi SA, Ventura VV, Qazi O, Harding SV, Kitto GB, Estes DM, Dell A, Titball RW, Atkins TP, Brown KA, Hitchen PG, Prior JL.

Vaccine. 2010 Nov 3;28(47):7551-5. doi: 10.1016/j.vaccine.2010.08.058. Epub 2010 Sep 15.


Induction of protective immunity against Burkholderia pseudomallei using attenuated mutants with defects in the intracellular life cycle.

Breitbach K, Köhler J, Steinmetz I.

Trans R Soc Trop Med Hyg. 2008 Dec;102 Suppl 1:S89-94. doi: 10.1016/S0035-9203(08)70022-1.


Attenuated virulence and protective efficacy of a Burkholderia pseudomallei bsa type III secretion mutant in murine models of melioidosis.

Stevens MP, Haque A, Atkins T, Hill J, Wood MW, Easton A, Nelson M, Underwood-Fowler C, Titball RW, Bancroft GJ, Galyov EE.

Microbiology. 2004 Aug;150(Pt 8):2669-76.


Global map of growth-regulated gene expression in Burkholderia pseudomallei, the causative agent of melioidosis.

Rodrigues F, Sarkar-Tyson M, Harding SV, Sim SH, Chua HH, Lin CH, Han X, Karuturi RK, Sung K, Yu K, Chen W, Atkins TP, Titball RW, Tan P.

J Bacteriol. 2006 Dec;188(23):8178-88. Epub 2006 Sep 22.


Identification of a LolC homologue in Burkholderia pseudomallei, a novel protective antigen for melioidosis.

Harland DN, Chu K, Haque A, Nelson M, Walker NJ, Sarkar-Tyson M, Atkins TP, Moore B, Brown KA, Bancroft G, Titball RW, Atkins HS.

Infect Immun. 2007 Aug;75(8):4173-80. Epub 2007 May 21.


Quorum sensing negatively regulates multinucleate cell formation during intracellular growth of Burkholderia pseudomallei in macrophage-like cells.

Horton RE, Grant GD, Matthews B, Batzloff M, Owen SJ, Kyan S, Flegg CP, Clark AM, Ulett GC, Morrison N, Peak IR, Beacham IR.

PLoS One. 2013 May 21;8(5):e63394. doi: 10.1371/journal.pone.0063394. Print 2013.


A Burkholderia pseudomallei deltapurM mutant is avirulent in immunocompetent and immunodeficient animals: candidate strain for exclusion from select-agent lists.

Propst KL, Mima T, Choi KH, Dow SW, Schweizer HP.

Infect Immun. 2010 Jul;78(7):3136-43. doi: 10.1128/IAI.01313-09. Epub 2010 Apr 19.


A model of immunity to Burkholderia pseudomallei: unique responses following immunization and acute lethal infection.

Ulett GC, Labrooy JT, Currie BJ, Barnes JL, Ketheesan N.

Microbes Infect. 2005 Aug-Sep;7(11-12):1263-75. Epub 2005 Jun 8.


Heterologously type IV pilus expressed protein of Burkholderia pseudomallei is immunogenic but fails to induce protective immunity in mice.

Sangdee K, Waropastrakul S, Wongratanachewin S, Homchampa P.

Southeast Asian J Trop Med Public Health. 2011 Sep;42(5):1190-6.


Evaluation of a biodegradable microparticulate polymer as a carrier for Burkholderia pseudomallei subunit vaccines in a mouse model of melioidosis.

Schully KL, Bell MG, Prouty AM, Gallovic MD, Gautam S, Peine KJ, Sharma S, Bachelder EM, Pesce JT, Elberson MA, Ainslie KM, Keane-Myers A.

Int J Pharm. 2015 Nov 30;495(2):849-61. doi: 10.1016/j.ijpharm.2015.09.059. Epub 2015 Sep 28.


BPSS1504, a cluster 1 type VI secretion gene, is involved in intracellular survival and virulence of Burkholderia pseudomallei.

Hopf V, Göhler A, Eske-Pogodda K, Bast A, Steinmetz I, Breitbach K.

Infect Immun. 2014 May;82(5):2006-15. doi: 10.1128/IAI.01544-14. Epub 2014 Mar 4.


Role for the Burkholderia pseudomallei capsular polysaccharide encoded by the wcb operon in acute disseminated melioidosis.

Warawa JM, Long D, Rosenke R, Gardner D, Gherardini FC.

Infect Immun. 2009 Dec;77(12):5252-61. doi: 10.1128/IAI.00824-09. Epub 2009 Sep 14.


Burkholderia pseudomallei capsular polysaccharide conjugates provide protection against acute melioidosis.

Scott AE, Burtnick MN, Stokes MG, Whelan AO, Williamson ED, Atkins TP, Prior JL, Brett PJ.

Infect Immun. 2014 Aug;82(8):3206-13. doi: 10.1128/IAI.01847-14. Epub 2014 May 27.


Development of Burkholderia mallei and pseudomallei vaccines.

Silva EB, Dow SW.

Front Cell Infect Microbiol. 2013 Mar 11;3:10. doi: 10.3389/fcimb.2013.00010. eCollection 2013. Review.


Characterization of Burkholderia pseudomallei Strains Using a Murine Intraperitoneal Infection Model and In Vitro Macrophage Assays.

Welkos SL, Klimko CP, Kern SJ, Bearss JJ, Bozue JA, Bernhards RC, Trevino SR, Waag DM, Amemiya K, Worsham PL, Cote CK.

PLoS One. 2015 Apr 24;10(4):e0124667. doi: 10.1371/journal.pone.0124667. eCollection 2015.

Supplemental Content

Support Center